Acute Coronary Syndrome: Focus on Antiplatelet Therapy

Area of Science:

• Cardiology
• Internal Medicine
• Evidence-Based Practice

Background:

• The American Heart Association/American College of Cardiology released focused updates in 2014 for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) guidelines.
• Separate 2013 guidelines address ST-segment elevation myocardial infarction (STEMI) management.
• These updates incorporate new recommendations for dual antiplatelet therapy (DAPT).

Purpose of the Study:

• To review updated guidelines for acute coronary syndrome (ACS) management.
• To highlight changes in dual antiplatelet therapy recommendations, including the P2Y12 inhibitor ticagrelor.
• To provide nurses with a case study-based approach for clinical decision-making in NSTE-ACS and STEMI.

Main Methods:

• Review of 2014 focused updates to NSTE-ACS guidelines and 2013 STEMI guidelines.
• Case study-based analysis of clinical decision-making for antiplatelet therapy selection.
• Focus on updated recommendations for dual antiplatelet therapy, including ticagrelor.

Main Results:

• The updated guidelines provide specific recommendations for dual antiplatelet therapy in ACS.
• Ticagrelor, a P2Y12 inhibitor, is included in the updated recommendations.
• The guidelines impact clinical decision-making for antiplatelet selection based on patient characteristics.

Conclusions:

• Nurses require a strong understanding of current ACS treatment guidelines for evidence-based care.
• The case study approach facilitates understanding of guideline application in NSTE-ACS and STEMI.
• Updated recommendations, particularly regarding DAPT, are crucial for optimal patient management.